FluroTech Identifies Six Sites For Its High Volume COVID-19 Antigen Test Trial

FluroTech Ltd. (TSXV: TEST) and its subsidiary FluroTest Diagnostics Systems announced today that the clinical trials for its high volume COVID-19 rapid antigen testing system are pushing to its next phase. This trial is being conducted with contract research organization Toolbox Medical Innovations.

FluroTest reported that approximately 600 volunteer participants are currently being identified from six clinical sites across California, Texas, Colorado, Rhode Island, and Florida for the next phase of the trial. The participants are a mix of symptomatic and asymptomatic individuals and the identified sites will compare the diagnostic results from the company’s high volume antigen testing system and a comparator RT-PCR assay.

As reported previously, the clinical trial results will be used to apply for an emergency use authorization from the U.S. FDA and an interim order authorization from the Health Canada.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

FluroTech Ltd. last traded at $0.31 on the TSX Venture.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Sona Nanotech: Health Canada Evaluation Results Did Not Match Prior Analytical And Clinical Study Data

Sona Nanotech (CSE: SONA) this morning elaborated on its decision to withdraw its antigen test...

Monday, November 30, 2020, 09:16:04 AM

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM

CFIB Warns of Further Business Closures Across Canada in Wake of Additional COVID-19 Shutdowns

As some regions in Canada move to impose stricter COVID-19 conditions and lockdowns, an increasing...

Saturday, November 21, 2020, 03:36:00 PM

Pfizer-BioNTech COVID-19 Vaccine Trial For Ages 5-11 Returns Favorable Topline Results

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced this morning the topline results...

Monday, September 20, 2021, 09:17:00 AM

Denmark to Begin Offering Covid-19 ‘Vaccine Passport’ for Travelers in Early 2021

As the coronavirus pandemic continues to spiral out of control and decimate air travel around...

Thursday, January 14, 2021, 04:01:00 PM